017180.KO Myungmoon Phar
- Market cap
- KRW 37.5B
- P/E
- -
- P/B
- 0.38x
- ROE
- -4.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 017180.KO undervalued?
Graham numberThe Graham number of Myungmoon Phar cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Myungmoon Phar fundamental analysis
No fundamental analysis for Myungmoon Phar yet.
Myungmoon Phar stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Myungmoon Phar
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervo…
Full company profileMyungmoon Phar financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Myungmoon Phar annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 142B | 140B | 147B | 149B | 128B | 145B | 152B | 170B | 186B | 195B | 198B |
| Gross Profit | 76.2B | 79.2B | 74.5B | 68.4B | 49.0B | 62.3B | 78.1B | 95.4B | 105B | 107B | 113B |
| Operating Income | 10.1B | 7.47B | 4.94B | -14.3B | -29.0B | -5.88B | 6.43B | 964M | 1.93B | 6.83B | -1.09B |
| EBITDA | - | 14.5B | 7.06B | -10.9B | -19.0B | 646M | 10.6B | 4.52B | 5.67B | 11.7B | 3.30B |
| Net Income | 6.75B | 7.81B | 988M | -20.4B | -27.6B | -6.86B | 7.87B | -4.52B | -3.03B | 1.90B | -4.13B |
| EPS | - | 312 | 39 | -815 | -818 | -203 | 233 | -135 | -91 | 57 | -123 |
| Balance Sheet | |||||||||||
| Total Assets | 221B | 235B | 243B | 264B | 243B | 223B | 230B | 237B | 258B | 272B | 300B |
| Total Liabilities | 126B | 133B | 150B | 184B | 152B | 137B | 135B | 148B | 155B | 168B | 198B |
| Shareholders' Equity | 91.0B | 97.7B | 89.7B | 76.5B | 87.2B | 80.3B | 89.5B | 83.5B | 96.9B | 98.7B | 97.6B |
| Cash & Short-term Investments | 17.6B | 1.40B | 623M | 572M | 4.55B | 6.81B | 4.86B | 7.96B | 4.39B | 5.84B | 24.1B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 5.60B | 8.02B | 11.4B | -2.94B | -16.7B | 855M | 5.47B | -5.18B | -1.34B | -1.70B | -6.81B |
| Capital Expenditure | 9.46B | 18.9B | 10.9B | 12.0B | 2.01B | 375M | 1.95B | 2.99B | 1.40B | 6.83B | 4.37B |
| Free Cash Flow | - | -14.2B | 314M | -17.1B | -19.1B | 480M | 3.53B | -8.17B | -2.74B | -8.54B | -11.2B |
| Ratios | |||||||||||
| ROE | 7.4% | 8.0% | 1.1% | -26.7% | -31.7% | -8.6% | 8.8% | -5.4% | -3.1% | 1.9% | -4.2% |
| ROA | 3.1% | 3.3% | 0.4% | -7.7% | -11.4% | -3.1% | 3.4% | -1.9% | -1.2% | 0.7% | -1.4% |
| Net Profit Margin | 4.7% | 5.6% | 0.7% | -13.7% | -21.6% | -4.7% | 5.2% | -2.7% | -1.6% | 1.0% | -2.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Myungmoon Phar dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Dec 27, 2017
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | KRW 2.39B | 95 | 241.8% |
| 2017 | KRW 1.15B | 46 | 14.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.020921:1 on Jan 3, 2018.
Who owns Myungmoon Phar
- Insiders 23.77%
- Institutions 0.04%
- Public & others 76.19%
- Shares outstanding 34.0M
- Free float 26.1M
Myungmoon Phar company profile
- Company name
- Myungmoon Phar
- Ticker
- 017180.KO
- ISIN
- KR7017180001
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 319
- Fiscal year end
- December
- Address
- 7, Gangnam-daero, Seoul, South Korea, 06258
- Phone
- 82 2 6711 2000
- Website
- mmpharm.co.kr
About Myungmoon Phar
MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, antidiarrheal agents, digestive system products, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products. In addition, it offers health supplements, quasi drugs, and blended juices. MYUNGMOON Pharm co.,Ltd was founded in 1983 and is headquartered in Seoul, South Korea.
Myungmoon Phar management
4- Mr. Kyu-Huok LeeChairperson & President · born 1949
- Cheol-han BaeChief Executive Officer
- Yong-Kyeong SeongManaging Director and Development Support Director · born 1964
- Won-Sann SeoDirector of Chungcheong & Honam Region and Director · born 1959